Life sciences researchers go shopping for molecules at Research and Diagnostic Systems The company (aka R&D Systems) is the primary subsidiary of TECHNE and manufactures and sells the tools used in life sciences research. Its biotechnology division offers thousands of proteins, antibodies, stem cells, and other handy stuff for researchers. Its BiosPacific subsidiary supplies biological ingredients to makers of in vitro diagnostic kits. R&D Systems' hematology division sells the blood components and equipment used to calibrate blood analysis equipment. Clients include pharmaceutical and biotechnology companies and academic and institutional research facilities.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

Natrol, Inc. company was founded in 1980 and is headquartered in Chatsworth, California. Natrol, Inc. manufactures and distributes nutritional products. The company offers nutritional and dietary supplements, functional herbal teas, and sports nutrition products for heart and digestive health, weight management and energy, mood and sleep support, eye and joint health, and children's and brain health. It also provides Natrol Immune Boost for the wellness of bodys immune system. In addition, the company manufactures supplements for third parties. It offers its products through retailers in the United States and subsidiaries in the United Kingdom and Hong Kong, as well as through distribution partners internationally.

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

GlaxoSmithKline Argentina has manufacturing and supply operations, as well as units devoted to consumer healthcare (dermatological, analgesic, oral care, gastrointestinal relief, and vitamin products) and to pharmaceutical products (anesthetic, antibiotic, oncologic, respiratory, and other drugs, as well as vaccines). A unit of GlaxoSmithKline, GSK Argentina also conducts research and pharmaceutical trials for its parent. Areas of focus include rheumatoid arthritis, epilepsy, diabetes, oncology, and Alzheimer's. The company's manufacturing and supply operations operate a production facility and export GSK goods to other parts of Central America.

Synarc, Inc. provides medical image-analysis, subject-recruitment, and biochemical-marker services to execute clinical trials for life-science industry clients. The company’s services include protocol design, imaging-site selection and training, imaging equipment monitoring, imaging quality assurance, centralized image analysis, centralized biochemical-marker assays, data management, project management, reporting and medical writing, and regulatory consulting and liaison with global agencies. It offers its services in various therapeutic areas, including cardiology, metabolic disorders, neurovascular diseases, neurology, oncology, orthopedics, osteoarthritis, osteoporosis, and rheumatoid arthritis. Synarc also operates clinical research centers in Europe, China, and Brazil. The company, formerly known as Advanced Imaging Research Services, Inc., was founded in 1998 and is based in San Francisco, California with additional offices in the United States, Denmark, France, Germany, Poland, the Czech Republic, Romania, Lithuania, Estonia, Brazil, Hong Kong, and China.

Actavis is Icelandic for generic. Iceland-based Actavis Group is one of the world's largest generic pharmaceuticals producers. Actavis company has about 350 drugs in its development pipeline, and nearly 1,000 products on the market across a variety of therapeutic classes (among them cardiovascular, gastrointestinal, and oncology). It also manufactures generic hospital products, including antibiotics, anesthetics, and painkillers. Actavis makes drugs in pill, injectable, suppository, and other forms. Subsidiary Medis distributes its drugs worldwide. Actavis, which was founded in 1956, is controlled by chairman Thor Bjorgolfsson through his investment vehicle Novator. At the company's helm is CEO Sigurdur Oli Olafsson.

Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas. Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.